Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

2672 - Changes in clinico-pathological characteristics of vulvar cancer in Japan: increasing oldest-old, stage-shifting, and decreasing cohort-level survival


29 Sep 2019


Poster Display session 2


Shin Nishio


Annals of Oncology (2019) 30 (suppl_5): v403-v434. 10.1093/annonc/mdz250


S. Nishio1, K. Matsuo2, T. Shibata3, S. Yamaguchi4, H. Kanao5, K. Takehara6, N. Kado7, A. Tozawa8, H. Tokunaga9, T. Matsunaga10, H. Kato11, K. Horie12, A. Kikuchi13, T. Enomoto14, M. Mikami15

Author affiliations

  • 1 Obstetrics And Gynecology, Kurume University, 830-0011 - Kurume/JP
  • 2 Obstetrics And Gynecology, University of Southern California, 90033 - Los Angeles/US
  • 3 Molecular Life Sciences, Tokai University, 259-1193 - Isehara/JP
  • 4 Gynaecology, Hyogo Cancer Center, Akashi, Hyogo/JP
  • 5 Gynecologic Oncology, Cancer Institute Hospital, Tokyo/JP
  • 6 Gynaecology, Shikoku Cancer Center, Ehime/JP
  • 7 Gynecologic Oncology, Shizuoka Cancer Center, Shizuoka/JP
  • 8 Obstetrics And Gynecology, St. Marianna University, Kawasaki/JP
  • 9 Obstetrics And Gynecology, Tohoku University, Sendai/JP
  • 10 Obstetrics And Gynecology, Yokohama City University Hospital, Yokohama/JP
  • 11 Gynecology, Kanagawa Cancer Center, Yokohama/JP
  • 12 Depertment Of Gynecology, Saitama Cancer Center, 362-0806 - Saitama/JP
  • 13 Gynecology, Niigata Cancer Center Hospital, Niigata/JP
  • 14 Obstetrics Adn Gynecology, Niigata University Medical and Dental Hospital, 951-8520 - Niigata/JP
  • 15 Obstetrics And Gynecology, Tokai University Hospital, Isehara/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2672


Vulvar cancer is a rare malignancy. Its occurrence in Japan is 1/6-1/10 of that in the Western countries. Population-based statisics for vulvar cancer has been missing in Japan. To examine trends in clinico-pathological characteristics of vulvar cancer in Japan.


This is a nationwide retrospective study examining consecutive cases of women with invasive vulvar cancer in Japan between 2001-2010 (n = 1,061). Temporal trends of demographics, tumor characteristics, and survival outcome were assessed with cohort-level analysis. The National Cancer Institute’s Surveillance, Epidemiology, and End Result Program served as the external validation (n = 10,154).


The number of oldest-old women aged ≥80 years significantly increased from 18.0% to 30.6% (70.5% relative increase) over time. There was a stage-shift observed, and stage I disease decreased from 43.0% to 34.0% (21.0% relative decrease) whereas tumors with inguino-femoral nodal or distant metastasis increased from 23.2% to 35.6% (53.3% relative increase) during the study period (P < 0.05). The number of women who underwent surgical treatment decreased from 84.0% to 69.7% (17.0% relative decrease) whereas utilization of radiotherapy increased from 34.4% to 43.2% (25.7% relative increase) over time (P < 0.05). In the cohort-level analysis, the 5-year survival rates significantly decreased between 2001-2010 (P < 0.05): 66.9% to 51.0% for progression-free survival (23.7% relative decrease), 79.5% to 67.9% for cause-specific survival (14.6% relative decrease), and 74.9% to 62.3% for overall survival (16.9% relative decrease). In the patient-level analysis, oldest-old women were less likely to undergo surgical treatment and independently associated with decreased survival (all, P < 0.05). In the US cohort, the number of oldest-old women (25.2% to 27.8%) and the 5-year cause-specific survival rate (81.8% to 79.9%) stayed unchanged during the study period (all, P > 0.05).


Demographics and outcomes of vulvar cancer in Japan have significantly changed during the study period: Increasing oldest-old population and stage-shift to more metastatic disease resulted in cohort-level decrease in survival rates.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.